# NCT02143466 (NCT02143466)

> AZD9291 in Combination With Ascending Doses of Novel Therapeutics

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02143466
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Advanced Non Small Cell Lung Cancer
- Interventions: Part A - AZD9291 in combination with AZD6094; Part A - AZD9291 in combination with continuous selumetinib (Asian subjects); Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects); Part A - AZD9291 in combination with intermittent selumetinib; Part A - AZD9291 in combination with MEDI4736; Part B - AZD9291 in combination with AZD6094; Part B - AZD9291 in combination with selumetinib; Part B - AZD9291 in combination with MEDI4736; Part C - AZD6094 monotherapy (Japan only); Part C - AZD9291 in combination with AZD6094 (Japan only); Part D - AZD9291 in combination with AZD6094
- Enrollment: 344
- Primary outcome: Number of participants with Adverse Events and/or Dose Limiting Toxicities as a Measure of Safety and Tolerability of AZD9291 when given in combination with AZD6094 or selumetinib
- Primary outcome: Number of participants with Adverse Events as a measure of Safety and Tolerability of AZD9291 when given in combination with AZD6094 or selumetinib

## Commentary we found

- Podcasts: 4
- X threads: 3
- YouTube: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct02143466

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02143466", "email": "<work email>"}; the inbox owner confirms by the emailed link.